Triflupromazine

Triflupromazine

Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
MedlinePlus	a600010
ATC code	N05AA05 (WHO)
Legal status
Legal status	US: ℞-only
Identifiers
IUPAC name N,N-dimethyl-3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propan-1-amine
CAS Number	146-54-3 Y
PubChem CID	5568
IUPHAR/BPS	4330
DrugBank	DB00508 N
ChemSpider	5367 N
UNII	RO16TQF95Y
KEGG	D00390 N
ChEBI	CHEBI:9711 N
ChEMBL	CHEMBL570 N
ECHA InfoCard	100.005.158
Chemical and physical data
Formula	C18H19F3N2S
Molar mass	352.418 g/mol
3D model (Jmol)	Interactive image
SMILES CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F
InChI InChI=1S/C18H19F3N2S/c1-22(2)10-5-11-23-14-6-3-4-7-16(14)24-17-9-8-13(12-15(17)23)18(19,20)21/h3-4,6-9,12H,5,10-11H2,1-2H3 N Key:XSCGXQMFQXDFCW-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Triflupromazine (Vesprin) is an antipsychotic medication of the phenothiazine class. Among different effects of triflupromazine indication for use of this drug is severe emesis. Due to its potential side effects (triflupromazine has higher risk for side effects than many other antipsychotics) it is not gold standard in antiemetic therapy.

Serious side effects of triflupromazine can be akathisia and tardive dyskinesia as well as the rare, but potentially fatal, neuroleptic malignant syndrome.